Table 1 Main clinical features and treatment variables of all DLBCL treated with intense chemo-immunotherapy program with final ASCT consolidation

From: High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression

 

All DLBCL patients

Naïve DLBCL

Relapsed DLBCL

 

All

Double exp

Not double exp

P-value

All naïve pts

Naïve double exp

Naïve not double exp

P-value

All relapsed pts (69)

Relapsed double exp

Relapsed not double exp

P-value

Male

84/140 (60%)

26/38 (68.4%)

58/102 (57%)

NS

39/71 (54.9%)

13/20 (65%)

26/51 (51%)

NS

45/69 (65.2%)

13/18 (72.2%)

32/51 (62.7%)

NS

Ann Arbor stage>2

110/138 (80%)

26/37 (70%)

84/101 (83%)

NS

65/71 (91.5%)

19/20 (95%)

46/51 (90%)

NS

45/67 (67.1%)

7/17 (41.1%)

38/50 (76%)

NS

Age>60

48/140 (34%)

10/38 (26%)

38/102 (37%)

NS

24/71 (33.8%)

5/20 (25%)

19/51 (37%)

NS

24/69 (34.7%)

5/18 (27.7%)

19/51 (37.2%)

0.01

ECOG⩾2

26/140 (18.5%)

3/38 (8%)

23/102 (23%)

0.05

18/71 (25.3%)

2/20 (10%)

16/51 (31%)

NS

8/69 (11.5%)

1/18 (5.55%)

7/51 (13.7%)

NS

High LDH

60/133 (45%)

13/35 (37%)

47/98 (48%)

NS

41/70 (58.5%)

12/20 (60%)

29/49 (59%)

NS

19/63 (30.1%)

1/15 (6.66%)

18/48 (37.5%)

0.01

Bulky

71/137 (52%)

21/38 (55%)

50/99 (51%)

NS

38/68 (55.8%)

12/20 (60%)

26/48 (54%)

NS

33/69 (47.8%)

9/18 (50%)

24/51 (47%)

NS

Extranodal sites⩾2

43/140 (30%)

10/38 (26%)

33/102 (32%)

NS

25/71 (35%)

6/20 (30%)

19/51 (37%)

NS

18/69 (26%)

4/18 (22.2%)

14/51 (27.4%)

NS

IPI⩾2

96/139 (70%)

22/38 (59%)

74/101 (73%)

NS

59/70 (84%)

15/20 (60%)

44/50 (88%)

NS

37/69 (53%)

7/18 (40%)

30/51 (59%)

NS

ASCT performed

82/140 (59%)

20/38 (53%)

62/102 (61%)

NS

55/71 (77%)

14/20 (70%)

41/51 (80%)

NS

27/69 (39%)

6/18 (33.3%)

21/51 (41%)

NS

Conditioning

 CT

63/82 (77%)

17/20 (85%)

46/62 (74%)

NS

39/55 (70.9%)

12/14 (85.7%)

27/41 (66%)

NS

23/27 (85%)

5/6 (83%)

18/21 (86%)

NS

 HD-Zevalin

19/82 (23%)

3/20 (15%)

16/62 (25%)

NS

16/55 (29%)

2/14 (14.2%)

14/41 (34%)

NS

4/27 (15%)

1/6 (17%)

3/21 (14%)

NS

Status pre ASCT

 Complete remission

68/82 (83%)

16/20 (80%)

52/62 (84%)

NS

46/55 (84%)

11/14 (78%)

34/41 (83%)

NS

22/27 (81%)

5/6 (83%)

17/21 (81%)

NS

 Partial remission

12/82 (15%)

3/20 (15%)

10/62 (16%)

NS

8/55 (15%)

2/14 (14%)

7/41 (17%)

NS

4/27 (15%)

1/6 (17%)

3/21 (14%)

NS

 Stable disease

2/82 (2%)

1/20 (5%)

0

NS

1/55 (2%)

1/14 (7%)

0

NS

1/27 (4%)

0

1/21 (5%)

NS

Reason for no ASCT

 Disease

47/58 (81%)

16/18 (80%)

31/40 (77%)

NS

12/16 (87.5%)

6/6 (100%)

6/10 (60%)

NS

34/42 (81%)

10/12 (83%)

24/30 (80%)

NS

 Poor mobilizer

3/58 (5.5%)

1/18 (11.1%)

2/40 (5%)

NS

0/16 (0%)

0/0 (%)

0 (0%)

NS

3/42 (7%)

1/12 (8.3%)

2/30 (6%)

NS

 Adverse event

7/58 (12%)

1/18 (13.3%)

6/40 (15.5%)

NS

4/16 (25%)

0/6 (0%)

4/10 (40%)

NS

4/42 (9.5%)

1/12 (8.3%)

3/30 (10%)

NS

 Other

1/58 (1.5%)

0

1/40 (2.5%)

NS

–

–

–

–

1/42 (2.4%)

0/0 (0%)

1/30 (4%)

NS

 MYC>40%

65/140 (46%)

38/38 (100%)

27/102 (26%)

0.003

31/71 (43.6%)

20/20 (100%)

11/51 (21%)

<0.0001

34/69 (49.2%)

18/18 (100%)

16/51 (31.3%)

<0.0001

 BCL2>70%

78/140 (55%)

38/38 (100%)

40/102 (39%)

<0.0001

37/71 (52.1%)

20/20 (100%)

17/51 (33%)

<0.0001

41/69 (59.4%)

18/18 (100%)

23/51 (45%)

<0.0001

 MYC/BCL2 co-expression

38/140 (27%)

38/38 (100%)

0/102 (0%)

<0.0001

20/71 (28.1%)

20/20 (100%)

0/51 (0%)

<0.0001

18/69 (26%)

18/18 (100%)

0/51 (0%)

<0.0001

 ABC-DLBCL

71/116 (61%)

22/29 (76%)

59/87 (69%)

NS

43/59 (73%)

11/14 (78%)

32/45 (71.1%)

NS

34/61 (56%)

13/18 (72%)

21/43 (49%)

NS

 Ki-67 High

90/128 (70%)

27/35 (77%)

63/93 (87%)

NS

40/57 (70%)

14/17 (82%)

26/40 (65%)

NS

44/66 (66%)

11/15 (73%)

33/51 (65%)

NS

  1. Abbreviations: ASCT, autologous stem cell transplant; LDH, lactate dehydrogenase; NS, nonsignificant.
Back to article page